Clinical trials: Obese Adults
Obesity & Overweight
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug…
- Trial name
- NCT07216651
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Closed Loop Medicine
Weight Management
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
- Trial name
- NCT05813795
- Testing
- Ecnoglutide Low Dosage, Ecnoglutide Medium Dosage, Ecnoglutide High Dosage
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet
The purpose of this study is to determine the efficacy and safety of topiramate compared with placebo in obese, Type 2 diabetic patients on a controlled diet.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231530
- Testing
- topiramate
- Volunteers
- 541 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes Mellitus (T2DM)
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
- Trial name
- NCT05761301
- Testing
- ALN-KHK
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Overweight and Obesity
ALY688-SR in Generally Healthy Overweight or Obese Adults
First in human study of ALY688-SR administered as a subcutaneous injection
- Trial name
- NCT04855565
- Testing
- ALY688-SR
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Allysta Pharmaceutical
Overweight or Obesity
A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered…
- Trial name
- NCT06938269
- Testing
- MWN109 tablet
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Hidradenitis Suppurativa
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS).
- Trial name
- NCT07830329
- Testing
- Olatorepatide
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity
The Acute Effect of Grains of Paradise (Aframomum Melegueta) on REE
Grains of paradise (Aframomumu melegueta) (GP), also known as Guinea pepper or Alligator pepper, belongs to the Zingiberaceae family, which is native to West Africa.
- Trial name
- NCT03894137
- Testing
- Grains of Paradise (Aframomum Melegueta)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Plexus Worldwide
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
- Trial name
- NCT07399678
- Testing
- ALV-100
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alveus Therapeutics, Inc.
Metabolic Syndrome, Pre-diabetes
Effect of Pasteurized Akkermansia Muciniphila on Insulin Resistance in Otherwise Healthy Subjects With Dysglycaemia
The purpose of this study is to demonstrate the efficacy of pasteurized Akkermansia muciniphila (pAKK) in improving insulin sensitivity in hyperglycaemic, but otherwise healthy persons with metabolic syndrome.
- Conditions
- Metabolic Syndrome, Pre-diabetes, Overweight and Obesity
- Trial name
- NCT05114018
- Testing
- Pasteurized A. muciniphila
- Where
- 2 sites in Germany, Ireland
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- A-Mansia Biotech S.A.
Overweight, Obesity
A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo
The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity or overweight following weight loss.
- Trial name
- NCT07757087
- Testing
- NNC0487-0111, LED
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Overweight , Obesity
TRPTI Metabolic and GLP-1 Pharmacodynamic Study
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older).
- Trial name
- NCT07850466
- Testing
- TRPTI
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112
1. Study Objective <Part 1> To evaluate the safety and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after multiple oral administration in healthy female subjects.
- Trial name
- NCT04703764
- Testing
- HSG4112
- Where
- 2 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Glaceum
Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity
This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 36-weeks' treatment period, and a 1-week safety follow-up visit period.
- Trial name
- NCT06820099
- Testing
- HRS-7535 tablet
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Overweight, Obesity
Individual Factors Related to Chronic Low-grade Inflammation and Cardiometabolic Disease Risk
The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.
- Conditions
- Overweight, Obesity, Metabolic Syndrome, Healthy
- Trial name
- PINEAPPL (NCT06355544)
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Integrative Phenomics
Overweight, Obesity
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese.
- Trial name
- NCT05677867
- Testing
- Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight or Obesity Without Diabetes
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
This study will test olatorepatide (study drug) to determine whether it can help treat overweight or obesity. In this study we will test how safe and how well olatorepatide works compared to placebo in people who are overweight…
- Trial name
- RISE-1 (NCT07896265)
- Testing
- Olatorepatide
- Volunteers
- 3,000 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight, Obesity
A Study Collecting Remote Data in People With an Overweight Condition or Obesity on a Weight Management Program
The purpose of this study is to collect health data related from participants living with an overweight condition in a decentralised clinical study set-up.
- Trial name
- NCT06805539
- Testing
- No treatment given
- Where
- Denmark
- Volunteers
- 146 people
- Sponsor
- Novo Nordisk A/S
Apnea, Sleep Disorders
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive…
- Conditions
- Apnea, Sleep Disorders, Overweight and/or Obesity
- Trial name
- VESPER-OSA 2 (NCT07881757)
- Testing
- Berobenatide
- Where
- 2 sites in United States
- Volunteers
- 258 people
- Sponsor
- Pfizer